A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice
Tapani Ruutu,Alois Gratwohl,T. de Witte,Boris V. Afanasyev,J. F. Apperley,Almalina Bacigalupo,Francesco Dazzi,Peter Dreger,R. F. Duarte,Jürgen Finke,Laurent Garderet,Hildegard T. Greinix,Ernst Holler,Kröger N,Anita Lawitschka,Mohamad Mohty,Arnon Nagler,Jakob Passweg,Olle Ringdén,Gérard Socié,Jorge Sierra,Anna Sureda,Wieslaw Wiktor-Jedrzejczak,Alejandro Madrigal,Dietger Niederwieser +24 more
TL;DR: Recommendations for prophylaxis and treatment of GVHD in the most common allogeneic transplant setting, transplantation from an HLA-identical sibling or unrelated donor for standard risk malignant disease are proposed.
Journal ArticleDOI
A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12‐triggered integrin activation but not in chemokine‐triggered motility of human T lymphocytes and CD34+ cells
Tanja Nicole Hartmann,Tanja Nicole Hartmann,Valentin Grabovsky,Ronit Pasvolsky,Ziv Shulman,Eike C. Buss,Eike C. Buss,Asaf Spiegel,Arnon Nagler,Tsvee Lapidot,Marcus Thelen,Ronen Alon +11 more
TL;DR: It is reported that CXCR7 fails to support on its own any CXCL12‐triggered integrin activation or motility in human T lymphocytes or CD34+ progenitors, and its blocking can be useful for therapeutic interference with CX CR4‐mediated activation of integrins.
Journal ArticleDOI
Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
Mohamad Mohty,Myriam Labopin,Liisa Volin,Alois Gratwohl,Gérard Socié,Jordi Esteve,Reza Tabrizi,Arnon Nagler,Vanderson Rocha +8 more
TL;DR: It is concluded that RIC allo-SCT from a human leukocyte antigen-identical donor is a potential therapeutic option for acute lymphoblastic leukemia patients aged ≥ 45 years in complete remission and not eligible for MAC allo -SCT.
Journal ArticleDOI
Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis.
Ekaterina Garbuzenko,Arnon Nagler,Dalia Pickholtz,Philippe Gillery,Reuven Reich,François-Xavier Maquart,Francesca Levi-Schaffer +6 more
TL;DR: Background Mast cells, the key cells of immediate hypersensitivity type reactions, have also been postulated to have a central role in influencing tissue remodelling and fibrosis occurring in the skin.
Journal ArticleDOI
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha,Christian Chabannon,Peter Bader,Grzegorz W. Basak,Halvard Bonig,Fabio Ciceri,Selim Corbacioglu,Rafael F. Duarte,Hermann Einsele,Michael Hudecek,Marie José Kersten,Ulrike Köhl,Jürgen Kuball,Stephan Mielke,Mohamad Mohty,John Murray,Arnon Nagler,Stephen P. Robinson,Riccardo Saccardi,Fermín Sánchez-Guijo,John A. Snowden,Micha Srour,Jan Styczyński,Alvaro Urbano-Ispizua,Patrick Hayden,Nicolaus Kröger +25 more
TL;DR: These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis.